Recurrent Guillain-Barre syndrome following vaccination
- PMID: 22267712
- DOI: 10.1093/cid/cir960
Recurrent Guillain-Barre syndrome following vaccination
Abstract
Background: Guillain-Barré syndrome (GBS) is an acute polyradiculopathy, thought to be autoimmune, which has been reported following vaccinations. The Advisory Committee on Immunization Practices recommends not administering influenza vaccine to individuals who have had a history of GBS within 6 weeks of a prior influenza vaccination if they are not at high risk of severe complications from influenza illness.
Methods: We identified GBS cases from the Kaiser Permanente Northern California databases from 1995 into 2006 using hospital discharge codes; each medical record was neurologist-reviewed and only GBS-confirmed cases were included for follow-up. We followed confirmed cases through 2008 for vaccinations and recurrent GBS.
Results: We identified 550 cases of GBS over 33 million person-years. Following their GBS diagnoses, 989 vaccines were given to 279 of these individuals, including 405 trivalent inactivated influenza vaccines (TIV) administered to 107 individuals with a prior diagnosis of GBS. Among the 550 total cases of GBS, 18 initially had onset within 6 weeks of TIV; of these, 2 were revaccinated with TIV without a recurrence of GBS. Only 6 individuals of 550 (1.1%) had a second (recurrent) diagnosis of GBS. Among these 6 individuals, none had any vaccine exposure at all in the 2 months prior to the second onset of GBS.
Conclusions: In our population of over 3 million members, during an 11-year period, risk of GBS recurrence was low. There were no cases of recurrent GBS after influenza vaccination and none within 6 weeks after any vaccine.
Similar articles
-
Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence.Clin Infect Dis. 2014 Apr;58(8):1149-55. doi: 10.1093/cid/ciu005. Epub 2014 Jan 9. Clin Infect Dis. 2014. PMID: 24415636 Review.
-
Lack of association of Guillain-Barré syndrome with vaccinations.Clin Infect Dis. 2013 Jul;57(2):197-204. doi: 10.1093/cid/cit222. Epub 2013 Apr 11. Clin Infect Dis. 2013. PMID: 23580737
-
Safety of influenza vaccines.Curr Opin Allergy Clin Immunol. 2012 Aug;12(4):383-8. doi: 10.1097/ACI.0b013e328354395d. Curr Opin Allergy Clin Immunol. 2012. PMID: 22766619 Review.
-
Preliminary results: surveillance for Guillain-Barré syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine - United States, 2009-2010.MMWR Morb Mortal Wkly Rep. 2010 Jun 4;59(21):657-61. MMWR Morb Mortal Wkly Rep. 2010. PMID: 20520590
-
Guillain-Barré syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005).J Clin Neuromuscul Dis. 2009 Sep;11(1):1-6. doi: 10.1097/CND.0b013e3181aaa968. J Clin Neuromuscul Dis. 2009. PMID: 19730016
Cited by
-
Evaluating algorithms for identifying incident Guillain-Barré Syndrome in Medicare fee-for-service claims.Glob Epidemiol. 2024 May 3;7:100145. doi: 10.1016/j.gloepi.2024.100145. eCollection 2024 Jun. Glob Epidemiol. 2024. PMID: 38746856 Free PMC article.
-
Guillain-Barré Syndrome Following the Administration of Adenovirus Vector-Based COVID-19 Vaccine.Cureus. 2023 Jul 23;15(7):e42316. doi: 10.7759/cureus.42316. eCollection 2023 Jul. Cureus. 2023. PMID: 37614248 Free PMC article.
-
Vaccine patterns among patients diagnosed with Guillain-Barré Syndrome and matched counterparts in a Medicare supplemental population, 2000-2020.Vaccine. 2023 Sep 7;41(39):5763-5768. doi: 10.1016/j.vaccine.2023.08.014. Epub 2023 Aug 10. Vaccine. 2023. PMID: 37573203
-
Deciphering changes in the incidence of the Guillain-Barré syndrome during the COVID-19 pandemic: a nationwide time-series correlation study.BMJ Neurol Open. 2022 Dec 30;4(2):e000378. doi: 10.1136/bmjno-2022-000378. eCollection 2022. BMJ Neurol Open. 2022. PMID: 36618976 Free PMC article.
-
Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age.Hum Vaccin Immunother. 2022 Nov 30;18(6):2099142. doi: 10.1080/21645515.2022.2099142. Epub 2022 Aug 10. Hum Vaccin Immunother. 2022. PMID: 35947774 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical